Novo Nordisk A/S Continues Its Comeback

Novo Nordisk A/S Continues Its Comeback

Novo Nordisk (NYSE: NVO) released earnings for the first half of 2017, and while revenue growth wasn't spectacular, considering how last year went for the diabetes specialist, investors will take it.

Metric

H1 2017

Continue reading

Source: Fool.com